1-2 of 2
Oliver Ammann-Mwathi
Close
Sort by
Journal Articles

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Veronika Buxhofer-Ausch, Heinz Gisslinger, MD, Josef Thaler, MD, Ernst Schlögl, MD, Gunther Gastl, MD Prof, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Sarita Ban, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Martin Schalling, MSc, Maria Theresa Krauth, MD, Nicole C.C. Them, Michael Zörer, Oliver Ammann-Mwathi, Pavla Kadlecova, Oleh Zagrijtschuk, Christoph Klade, Richard Greil, MD
Journal: Blood
Blood (2015) 126 (23): 1603.
https://doi.org/10.1182/blood.V126.23.1603.1603
Published: 2015
Journal Articles

Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, Josef Thaler, MD, Ernst Schlögl, MD, Gunther Gastl, MD Prof,, Dominik Wolf, MD, Martin Schalling, MSc, Bettina Gisslinger, Sarita Ban, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, Maria Theresa Krauth, MD, Nicole C.C. Them, Robert Kralovics, PhD, Michael Zörer, Oliver Ammann-Mwathi, Pavla Kadlecova, Oleh Zagrijtschuk, Christoph Klade, Richard Greil, MD
Journal: Blood
Blood (2015) 126 (23): 4056.
https://doi.org/10.1182/blood.V126.23.4056.4056
Published: 2015